You are here: Industry Insights > AstraZeneca

News List

Forxiga Approved in Japan for Chronic Heart Failure americanpharmaceuticalreview
December 16, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care.
AstraZeneca to test combination of AZD1222 and Sputnik V vaccines europeanpharmaceuticalreview
December 15, 2020
AstraZeneca will begin testing whether they can improve the efficacy of AZD1222 by combining it with the Ad26 human adenoviral vector from Russia’s Sputnik V vaccine.
EU for AZ' COPD maintenance therapy pharmatimes
December 15, 2020
AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been approved in the EU for maintenance treatment in adults with moderate to severe chronic obstructive pulmonary disease (COPD).
AstraZeneca to acquire Alexion expresspharma
December 14, 2020
AstraZeneca and Alexion Pharmaceuticals have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Covishield can be available in first half of 2021 expresspharma
December 14, 2020
Serum Institute has currently applied with the DCGI for emergency authorization of Covishield in the country.
Enhertu scores ‘impressive’ new data in HER2 breast cancer pharmatimes
December 11, 2020
AstraZeneca (AZ) and Daiichi Sankyo have reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.
AstraZeneca’s vaccine shows efficacy in preventing symptomatic Covid-19 pharmaceutical-technology
December 10, 2020
AstraZeneca has reported that interim analysis from the Phase III programme of the Covid-19 vaccine, AZD1222, showed it is safe and effective at preventing symptomatic Covid-19.
NICE backs AZ' Calquence for chronic lymphocytic leukaemia pharmatimes
December 09, 2020
The National Institute for Health and Care Excellence has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia (CLL).
HALIX, AstraZeneca Ink Commercial COVID-19 Vax Mfg. Pact contractpharma
December 09, 2020
HALIX to provide large-scale GMP manufacture of AZD1222 at its cGMP facility in the Netherlands.
Calquence shows long-term efficacy and tolerability in MCL pharmatimes
December 08, 2020
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca's Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page